½ÃÀ庸°í¼­
»óǰÄÚµå
1363281

¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° µ¿Çâ(2023-2030³â)

Bioinformatics Market Size, Share & Trends Analysis Report By Product (Bioinformatics Platforms, Bioinformatics Services), By Application (Genomics, Cheminformatics, Metabolomics, Proteomics), By Region, And Segment Forecasts, 2023 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 77 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, ¼¼°è ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ½ÃÀåÀº 2023³âºÎÅÍ 2030³â±îÁö 13.7%ÀÇ CAGRÀ» ³ªÅ¸³»°í, 2030³â±îÁö 285¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹ÙÀÌ¿ÀÀǾàǰ ÀÓ»ó °³¹ßÀÇ °³Ã´°ú 3Â÷¿ø ¾à¹° ¼³°è ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ÇâÈÄ 5³â°£ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ, ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º µµ±¸ ¹× ºÐ¼® Ç÷§ÆûÀÇ °³¹ß ¹× ½Å±â¼ú µµÀÔÀº ÀÌ ½ÃÀåÀÇ ¼ºÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, »õ·Î¿î API ¹× ¹ÙÀÌ¿À ÀǾàǰÀÇ ½Å¼ÓÇÑ °³¹ß¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡µµ ÀÌ »ê¾÷ÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • À¯ÀüüÇÐ ÀÀ¿ë ºÐ¾ß°¡ 2022³â Å« ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀÔ´Ï´Ù. ÀǾàǰ °³¹ß ¹× ½ÃÄö½Ì ½ºÅ©¸®´×¿¡¼­ ¾à¸®À¯ÀüüÇп¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ´ë±Ô¸ð À¯Àüü µ¥ÀÌÅÍ °ü¸®¸¦ À§ÇÑ ±â¼ú ¹ßÀüÀÇ µµÀÔÀÌ ÀÌ Å« ºñÁßÀ» Â÷ÁöÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù.
  • ¹ÙÀÌ¿À ÄÁÅÙÃ÷ °ü¸® ºÐ¾ß´Â 2022³â 39.6%ÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù. µ¥ÀÌÅͺ£À̽º °ü¸®¿¡¼­ ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º µµ±¸¿Í ¼ÒÇÁÆ®¿þ¾îÀÇ »ç¿ë·üÀÌ ³ôÀº °ÍÀÌ Å« ºñÁßÀ» Â÷ÁöÇÏ´Â ÁÖ¿ä ÀÌÀ¯ Áß ÇϳªÀÔ´Ï´Ù.
  • ºÏ¹Ì°¡ 2022³â 43.6%ÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¸ÅÃâÀÇ ´ëºÎºÐÀº ¹Ì±¹°ú ij³ª´Ù¿¡¼­ ¹ß»ýÇϴµ¥, ÀÌ´Â ÀÌ Áö¿ª¿¡ ÃÖ°í ¼öÁØÀÇ ¿¬±¸ ±â°ü, Çмú ±â°ü ¹× »ý¹° Á¤º¸ÇÐ ±â¾÷ÀÌ ±¤¹üÀ§ÇÏ°Ô Á¸ÀçÇϱ⠶§¹®ÀÎ °ÍÀ¸·Î ºÐ¼®µË´Ï´Ù.
  • ´Ù¾çÇÑ '-omics' °ü·Ã ¿¬±¸ °³¹ß Áõ°¡¿Í ÀÌ·¯ÇÑ ¿¬±¸¿¡¼­ »ý¼ºµÇ´Â ¹æ´ëÇÑ ¾çÀÇ »ý¹°ÇÐÀû µ¥ÀÌÅÍ ÅëÇÕÀÇ Çʿ伺Àº ¾÷°è ±â¾÷µéÀÌ º¸´Ù ºü¸£°í È¿À²ÀûÀÌ¸ç ´ÙÀç´Ù´ÉÇÑ ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼ÒÇÁÆ®¿þ¾î ¹× Ç÷§ÆûÀÇ »ó¿ëÈ­¸¦ À§ÇÑ °³¹ß·Î À̾îÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °³¹ßÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ¹ÙÀÌ¿À ÄÁÅÙÃ÷ °ü¸® ºÐ¾ß´Â 2022³â 39.6%ÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù. µ¥ÀÌÅͺ£À̽º °ü¸®¿¡¼­ ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º µµ±¸¿Í ¼ÒÇÁÆ®¿þ¾îÀÇ »ç¿ë·üÀÌ ³ôÀº °ÍÀÌ Å« ºñÁßÀ» Â÷ÁöÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù.
  • ¶ÇÇÑ, ½ÃÄö½Ì ¹× ±¸Á¶ ºÐ¼® Ç÷§Æû ºÐ¾ß´Â Â÷¼¼´ë ½ÃÄö¼­ÀÇ ¹ßÀü°ú ÀüÀå À¯Àüü ¿¢¼Ø ½ÃÄö½ÌÀÇ ºñ¿ë Àý°¨À¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È 20% ÀÌ»óÀÇ CAGR·Î °¡Àå ºü¸¥ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº ÇâÈÄ 5³â°£ ÀÌ ½ÃÀå Àüü ¼ºÀå¿¡ Å« ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ÄÍÀÎÆ÷¸Åƽ½º ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È Å« ÆøÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¹ÙÀÌ¿À¸¶Ä¿ ¹ß°ß ¹× °³¹ß¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ÀÌ·¯ÇÑ ¼ºÀå Àü¸ÁÀÇ ÁÖ¿ä ¿øÀÎÀÔ´Ï´Ù. ÀǾàǰ °³¹ß °úÁ¤ÀÇ ºñ¿ë Àý°¨, ½Å¾à ½ÃÀå Ãâ½Ã ±â°£ ´ÜÃà, ÄÍÀÎÆ÷¸Åƽ½º ¹× ¾à¹° ¼³°è¸¦ ÅëÇÑ ½Å¾à °³¹ß ¼º°ø·ü Çâ»ó µîÀÌ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ´Ü¹éÁúüÇÐ ¿ëµµ´Â °¡±î¿î ¹Ì·¡¿¡ »ó´çÇÑ R&D ÅõÀÚ¸¦ À¯Ä¡ÇÏ°í ¿¹Ãø ±â°£ µ¿¾È À¯¸®ÇÑ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµÇ¸ç, 3Â÷¿ø ¾à¹° °³¹ß ±â¼úÀÇ °³¹ßÀº ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ºÏ¹Ì°¡ 2022³â 43.6%ÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¸ÅÃâÀÇ ´ëºÎºÐÀº ¹Ì±¹°ú ij³ª´Ù¿¡¼­ ¹ß»ýÇϴµ¥, ÀÌ´Â ÀÌ Áö¿ª¿¡ ÃÖ°í ¼öÁØÀÇ ¿¬±¸ ±â°ü, Çмú ±â°ü ¹× »ý¹° Á¤º¸ÇÐ ±â¾÷ÀÌ ³Î¸® ºÐÆ÷µÇ¾î Àֱ⠶§¹®ÀÔ´Ï´Ù. ºÐÀÚ»ý¹°ÇÐ ¹× °Ô³ð ½ÃÄö½Ì°ú °ü·ÃµÈ »õ·Ó°í Çõ½ÅÀûÀÎ ±â¼ú ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡°¡ ÀÌ Áö¿ª ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È 18.4%ÀÇ CAGR·Î °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â Áö¿ª ½ÃÀåÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼÷·ÃµÈ ¹ÙÀÌ¿ÀÁ¤º¸ÇÐÀÚÀÇ Á¸Àç¿Í ÀÌ Áö¿ªÀÇ IT ºÎ¹®ÀÇ °­·ÂÇÑ ¹ßÀüÀ¸·Î ÀÎÇØ ½ÅÈï °æÁ¦±¹¿¡ ´ëÇÑ ¾Æ¿ô¼Ò½Ì ¼­ºñ½º Á¦°ø ´É·ÂÀÌ Çâ»óµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, Á¤ºÎÀÇ Áö¿ø Á¤Ã¥µµ ¿¹Ãø ±â°£ µ¿¾È ÀÌ Áö¿ªÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • º¸±Þ°ú ¼ºÀå Àü¸Á ¸ÅÇÎ
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - PorterÀÇ Five Forces ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ½ÃÀå : Á¦Ç°º° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ½ÃÀå : Áß¿ä Æ÷ÀÎÆ®
  • ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ½ÃÀå : Á¦Ç° µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â°ú 2030³â
  • ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º Ç÷§Æû
    • ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º Ç÷§Æû ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018³â-2030³â
    • ¹è¿­ ºÐ¼® Ç÷§Æû
    • ¹è¿­ Á¶ÀÛ Ç÷§Æû
    • ¹è¿­ ¾ó¶óÀÌ¸ÕÆ® Ç÷§Æû
    • ±¸Á¶ ¹× ±â´É ºÐ¼® Ç÷§Æû
    • ±âŸ
  • ¹ÙÀÌ¿À ÄÁÅÙÃ÷ °ü¸®
    • ¹ÙÀÌ¿À ÄÁÅÙÃ÷ °ü¸® ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018³â-2030³â
    • ¹ü¿ë ¹ÙÀÌ¿À ÄÁÅÙÃ÷ Åø
    • Ư¼öÇÑ ¹ÙÀÌ¿À ÄÁÅÙÃ÷ Åø
  • ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼­ºñ½º
    • ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼­ºñ½º ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018³â-2030³â
    • ½ÃÄö½Ì
    • µ¥ÀÌÅÍ ºÐ¼® ¼­ºñ½º
    • µ¥ÀÌÅͺ£À̽º °ü¸® ¼­ºñ½º
    • ±âŸ ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼­ºñ½º

Á¦5Àå ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ½ÃÀå : ¿ëµµº° Àü¸Á

  • ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ½ÃÀå : Áß¿ä Æ÷ÀÎÆ®
  • ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ½ÃÀå : º° ¿òÁ÷ÀÓ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â°ú 2030³â
  • À¯ÀüüÇÐ
  • ºÐÀÚ °èÅëÇÐ
  • ´ë»çüÇÐ
  • ´Ü¹éÁúüÇÐ
  • Àü»çüÇÐ
  • Cheminformatics ¹× Drug Discovery
  • ±âŸ

Á¦6Àå ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ½ÃÀå : Áö¿ªº° Àü¸Á

  • Áö¿ªº° Àü¸Á
  • Áö¿ªº° ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ½ÃÀå : Áß¿ä Æ÷ÀÎÆ®
  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦7Àå °æÀï ±¸µµ

  • ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷ÀÇ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
  • ȸ»ç/°æÀï ºÐ·ù
    • DNAnexus Inc.
    • Seven Bridges Genomics
    • BGI Group
    • Partek Inc.
    • Thermo Fisher Scientific
    • Qiagen
    • Agilent Technologies
    • Illumina
    • PerkinElmer
LSH 23.10.31

Bioinformatics Market Growth & Trends:

The global bioinformatics market is expected to reach USD 28.5 billion by 2030, registering a CAGR of 13.7% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Growing clinical development of biopharmaceutical and increasing need for three-dimensional drug designing technology are expected to drive the market growth over the next five years.

Furthermore, the development of bioinformatics tools and analysis platforms coupled with the introduction of novel technologies are expected to be high impact rendering factors for the growth of this market. Increasing demand for faster development of novel API and biopharmaceuticals is also expected to enhance the growth of this industry.

Bioinformatics Market Report Highlights:

  • The genomics application segment accounted for a significant revenue share in 2022. Growing demand for pharmacogenomics in drug development and sequence screening and the introduction of technological advancements aimed at managing large sets of genomic data are key factors accounting for this large share.
  • The bio-content management segment led the market with a revenue share of 39.6% in 2022. High usage rates of bioinformatics tools and software in database management are one of the primary reasons attributed to its large share, as it efficiently provides easy data sharing with external databases and resources and promotes data integration.
  • North America dominated the market and accounted for a revenue share of 43.6% in 2022. The majority of the revenue is generated from the U.S. and Canada, driven by the extensive presence of top research organizations, academic institutions, and bioinformatics businesses in the region.
  • Growth in the number of research and development studies in various '-omics' related segments and the need for integration of the large amounts of biological data generated from these studies are also expected to encourage industry players to develop faster, more efficient, and versatile bioinformatics software cum platforms for commercialization.
  • The bio-content management segment led the market with a revenue share of 39.6% in 2022. High usage rates of bioinformatics tools and software in database management are one of the primary reasons attributed to its large share, as it efficiently provides easy data sharing with external databases and resources and promotes data integration.
  • Moreover, the sequence and structural analysis platform segment is expected to grow at the fastest CAGR of over 20% over the forecast period owing to the development of next-generation sequencing and expected reduction in the cost of whole genome exome sequencing. These factors are expected to have a significantly positive impact on the overall growth of this market in the next five years.
  • The cheminformatics segment is expected to expand substantially during the forecast period, wherein increasing demand for biomarker discovery and development is the primary reason for this expected growth. Cost reductions in the drug development process, reduced time for introducing a new drug in the market, and an increase in the success rate of drug discovery by cheminformatics and drug designing are expected to further boost this segment's growth.
  • Proteomic applications are expected to attract a considerable amount of R&D investment in the near future and witness lucrative growth over the forecast period. Developments in three-dimensional drug development technologies are further expected to boost the growth of this segment.
  • North America dominated the market and accounted for a revenue share of 43.6% in 2022. The majority of the revenue is generated from the U.S. and Canada, driven by the extensive presence of top research organizations, academic institutions, and bioinformatics businesses in the region. Increasing investments in the research & development of new and innovative technologies related to molecular biology and genome sequencing is expected to boost the regional market.
  • Asia Pacific is poised to be the fastest-growing regional market with a CAGR of 18.4% during the projection period. The presence of skilled and trained bioinformaticians and the expected strong development of the region's IT sector are anticipated to enhance the capability of providing outsourcing services to developed economies. Supportive government policies are also expected to drive the growth of this region over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Application
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Application outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Bioinformatics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Bioinformatics Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Bioinformatics Market: Product Estimates & Trend Analysis

  • 4.1. Bioinformatics Market: Key Takeaways
  • 4.2. Bioinformatics Market: Product Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Bioinformatics Platforms
    • 4.3.1. Bioinformatics platforms market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.2. Sequence analysis platforms
      • 4.3.2.1. Sequence analysis platforms market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.3. Sequence manipulation platforms
      • 4.3.3.1. Sequence manipulation platforms market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.4. Sequence alignment platforms
      • 4.3.4.1. Sequence alignment platforms market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.5. Structural and functional analysis Platforms
      • 4.3.5.1. Structural and functional analysis platforms market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.6. Others
      • 4.3.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Bio-content Management
    • 4.4.1. Bio-content management market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. Generalized Bio-content Tools
      • 4.4.2.1. Generalized Bio-content Tools market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. Specialized Bio-content Tools
      • 4.4.3.1. Specialized Bio-content Tools market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Bioinformatics Services
    • 4.5.1. Bioinformatics services market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.5.2. Sequencing
      • 4.5.2.1. Sequencing services market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.5.3. Data analysis services
      • 4.5.3.1. Data analysis services market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.5.4. Database management services
      • 4.5.4.1. Database management services market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.5.5. Other bioinformatics services
      • 4.5.5.1. Other bioinformatics services market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Bioinformatics Market: Application Outlook

  • 5.1. Bioinformatics Market: Key Takeaways
  • 5.2. Bioinformatics Market: Application Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Genomics
    • 5.3.1. Genomics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Molecular Phylogenetics
    • 5.4.1. Molecular phylogenetics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Metabolomics
    • 5.5.1. Metabolomics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Proteomics
    • 5.6.1. Proteomics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Transcriptomics
    • 5.7.1. Transcriptomics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.8. Cheminformatics and Drug Designing
    • 5.8.1. Cheminformatics and drug designing market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Other applications market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Bioinformatics Market Regional Outlook

  • 6.1. Regional Outlook
  • 6.2. Bioinformatics Market by Region: Key Takeaways
  • 6.3. North America
    • 6.3.1. North America Bioinformatics market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. U.S. Bioinformatics market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Canada Bioinformatics market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. UK market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Germany market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. France market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Italy market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Spain market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Denmark
      • 6.4.6.1. Denmark market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Sweden market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Norway
      • 6.4.8.1. Norway market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Japan market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. China market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. India market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Australia market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Thailand market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. South Korea market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Brazil market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Mexico market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Argentina market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. South Africa market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Saudi Arabia market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. UAE market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Kuwait market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
    • 7.2.1. DNAnexus Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Seven Bridges Genomics
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. BGI Group
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Partek Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Thermo Fisher Scientific
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Qiagen
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Agilent Technologies
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Illumina
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. PerkinElmer
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦